The Morrison Government has extended a temporary change to the continuous disclosure rules to give companies more wriggle room in updating shareholders during the coronavirus pandemic by six months, saying the change had allowed shareholders to remain informed while preventing “opportunistic class actions”.
German drug maker Boehringer has launched a Federal Court fight against rival Zoetis after coming up short in its opposition to two Zoetis patents for pig vaccine-related inventions.
A shareholder class action against Vocation that has spanned five years and spawned multiple cross claims against the failed training company’s auditor, law firm and individual directors, has reached an in-principle settlement.
Commonwealth Bank of Australia has resolved a lawsuit brought by a former general manager alleging he lost his job for blowing the whistle on a system allegedly used by staff to inflate their bonuses.
The Australian Competition Tribunal has shot down ACCC moves to restrict the use of buy now, pay later finance for the purchase of solar goods and other new energy technology products.
Ernst & Young is facing a claim for $12 million damages in a lawsuit over its auditing of collapsed soda ash maker Penrice.
The Australian Securities and and Investments Commission has won a $57.5 million judgment against two units of National Australia Bank for making misleading representations to superannuation customers regarding $100 million in fees charged for services they never received, far short of the $125 million sought by the corporate regulator.
Hungry Jack’s has released a new television ad poking fun at McDonald’s lawsuit alleging its new ‘Big Jack’ burger violates the US fast food giant’s intellectual property for its classic ‘Big Mac’, referred to in the ad as “some American burger”.
A former Maple Brown Abbott analyst has been sentenced to three years after pleading guilty to insider trading and communicating inside information in relation to $1.6 million in shares of collapsed video company Big Un.
US pharmaceutical giant Merck Sharp & Dohme has taken a unit of Indian generic manufacturer Lupin to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Januvia and Janumet.